Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibacterials - Oragenics

Drug Profile

Research programme: antibacterials - Oragenics

Alternative Names: Lantibiotics; MU 1140-S; MU-1140; MU1140 analogs - Oragenics; Mutacin 1140; OG 253; OG 716

Latest Information Update: 17 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Texas A&M University; University of Florida
  • Developer Intrexon Corporation; Oragenics Inc
  • Class Antibacterials; Bacteriocins; Cyclic peptides
  • Mechanism of Action Cell membrane permeability enhancers; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium difficile infections

Most Recent Events

  • 14 May 2019 Pharmacodynamics data from a preclinical studies in Clostridium difficile infections for OG 253 released by Oragenics
  • 03 May 2019 Oragenics announces intention to submit IND application for OG 716 for Clostridium difficile infections in 2019
  • 25 May 2018 Oragenics, Inc. and Texas A&M University System has patent protection for variants of the lantibiotic MU 1140 and other lantibiotics in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top